Genetic characteristics
• Autosomal recessive inheritance • Between 10% and 13% of individuals of northern European heritage are carriers of hereditary haemochromatosis • A candidate gene on chromosome 6, HFE (or HLA-H), was identified in 1996.' One mutation (C282Y) has been detected in as many as 11% of northern European white individuals tested, but is not found in African and Asian populations' 9
Natural history • Clinical manifestations result from accumulation of excess iron absorbed from the diet; they usually appear in the fourth to fifth decade in men, later in women owing to the protective effect of blood loss from menstruation and childbirth. Symptoms of iron overload are occasionally observed in young men and women • About 70% of men and 40% of women who are homozygous for hereditary haemochromatosis develop clinical manifestations at some point in their lives' • Clinical manifestations range from lethargy and abdominal pain to arthropathy, diabetes, hypogonadism (impotence in men and amenorrhoea in women), skin pigmentation, cardiomyopathy, and hepatic fibrosis and cirrhosis • Diagnosis and treatment before the occurrence of organ damage improves prognosis.' Among symptomatic individuals, iron depletion treatment can improve some, but not all, clinical manifestations -DNA based testing for HFE mutations after a positive TS screening test -Liver biopsy to assess the degree of liver damage (fibrosis or cirrhosis) and to quantify excess iron, based on hepatic parenchymal cell stainable iron (grade 1-4+) and liver iron concentration (umol/g dry weight). The hepatic iron index (umol/g dry weight divided by age at the time of biopsy) is helpful in differentiating hereditary haemochromatosis from alcoholic liver disease' -Quantitative phlebotomy, Removal of 5 g or more of iron before the packed cell volume falls is consistent with hereditary haemochromatosis Treatment • Initially remove 500 ml of blood (as in blood donation) once or twice a week until the packed cell volume begins to fall and TS and serum ferritin levels return to low normal • Then, remove 500 ml every two to six months to maintain low normal TS and serum ferritin levels
Unresolved screening issues
The case for population screening is not yet made because: • The size of the effect of screening on reducing morbidity and mortality is uncertain • There is a need for more detailed information on the prevalence and severity of hereditary haemochromatosis clinical manifestations according to age in the general population • A better understanding is needed of the correlations between genotype, iron status markers (TS, serum ferritin, hepatic iron), and clinical severity • The initial screening test of choice (TS or DNA testing) is unresolved • The best age for screening in men and women is not specified • Designs for delivering screening related services need to be developed and evaluated
